513 related articles for article (PubMed ID: 28399408)
1. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Seaman S; Zhu Z; Saha S; Zhang XM; Yang MY; Hilton MB; Morris K; Szot C; Morris H; Swing DA; Tessarollo L; Smith SW; Degrado S; Borkin D; Jain N; Scheiermann J; Feng Y; Wang Y; Li J; Welsch D; DeCrescenzo G; Chaudhary A; Zudaire E; Klarmann KD; Keller JR; Dimitrov DS; St Croix B
Cancer Cell; 2017 Apr; 31(4):501-515.e8. PubMed ID: 28399408
[TBL] [Abstract][Full Text] [Related]
2. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y; Lee J; Yang L; Hilton MB; Morris K; Seaman S; Edupuganti VVSR; Hsu KS; Dower C; Yu G; So D; Bajgain P; Zhu Z; Dimitrov DS; Patel NL; Robinson CM; Difilippantonio S; Dyba M; Corbel A; Basuli F; Swenson RE; Kalen JD; Suthe SR; Hussain M; Italia JS; Souders CA; Gao L; Schnermann MJ; St Croix B
Cell Rep; 2023 Dec; 42(12):113503. PubMed ID: 38019654
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
6. CD276 (B7-H3) Maintains Proliferation and Regulates Differentiation in Angiogenic Function in Late Endothelial Progenitor Cells.
Son Y; Kwon SM; Cho JY
Stem Cells; 2019 Mar; 37(3):382-394. PubMed ID: 30379377
[TBL] [Abstract][Full Text] [Related]
7. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
Kendsersky NM; Lindsay J; Kolb EA; Smith MA; Teicher BA; Erickson SW; Earley EJ; Mosse YP; Martinez D; Pogoriler J; Krytska K; Patel K; Groff D; Tsang M; Ghilu S; Wang Y; Seaman S; Feng Y; Croix BS; Gorlick R; Kurmasheva R; Houghton PJ; Maris JM
Clin Cancer Res; 2021 May; 27(10):2938-2946. PubMed ID: 33619171
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.
Lutz AM; Bachawal SV; Drescher CW; Pysz MA; Willmann JK; Gambhir SS
Clin Cancer Res; 2014 Mar; 20(5):1313-22. PubMed ID: 24389327
[TBL] [Abstract][Full Text] [Related]
9. CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1.
Durlanik S; Fundel-Clemens K; Viollet C; Huber HJ; Lenter M; Kitt K; Pflanz S
Sci Rep; 2021 Jul; 11(1):14849. PubMed ID: 34290311
[TBL] [Abstract][Full Text] [Related]
10. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
[TBL] [Abstract][Full Text] [Related]
11. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
12. A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature.
Khan KA; Kerbel RS
Cancer Cell; 2017 Apr; 31(4):469-471. PubMed ID: 28399405
[TBL] [Abstract][Full Text] [Related]
13. Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
Harland N; Maurer FB; Abruzzese T; Bock C; Montes-Mojarro IA; Fend F; Aicher WK; Stenzl A; Amend B
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563359
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Clin Cancer Res; ; . PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
